N/A N=83 Safety and Performance of the SUTUREFIX ULTRA and SUTUREFIX CURVED Suture Anchors in Shoulder and Hip Arthroscopic Repair
Instability, Joint
Primary: Clinical Success at 6 Months — 56 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=214 Treatment Shortening of MDR-TB Using Existing and New Drugs
Tuberculosis, Multidrug-Resistant
Primary: Treatment Success Rate — 60; 54 Participants
Phase 1 N=257 A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva
Healthy Volunteers
Primary: AUC0-last — 146000; 134000; 138000 day*ng/mL
N/A N=133 Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock
Septic Shock
Primary: Total Vasopressor Dose — 13.7; 13.1; 13.2; 11.3 mg
Phase 4 N=7 The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine
Vitamin B1 Deficiency · Thiamine Deficiency
Primary: Maximum Concentration (Cmax) of Thiamine in Plasma Between the Combination Arm(s) and Single Agent Arm — 15; 32 nM
Phase 1 N=32 Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics
Asthma
Primary: Number of Treatment-emergent Adverse Events and Serious Adverse Events — 19; 17; 12; 9 adverse events
N/A N=35 Comparison of Modified Vacuum-formed Retainers Versus Hawley Retainer
Orthodontic Retainers · Clinical Trial
Primary: Arch Width — 36.9; 37.65; 44.61; 46.31 milimeters
N/A N=2,108 The Impact of Telelactation Services on Breastfeeding Outcomes
Breastfeeding
Primary: Breastfeeding Duration 1 — 674; 639 Participants — p=0.08
Phase 1 N=95 Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
Huntington's Disease
Primary: Change From Baseline in the Following Clinical Endpoints at 3, 9, and 15 Months: cUHDRS, TFC, TMS, SDMT, SWR Test and IS — 0.19; -0.12; -0.76; -0.24 Scores on a scale
Phase 3 N=119 Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
Primary IgA Nephropathy
Primary: Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline — 0.67; 0.69 ratio
Phase 4 N=305 Extended Duration Artemether-lumefantrine Treatment for Malaria in Children
Uncomplicated Plasmodium Falciparum Malaria
Primary: AUC0-21d — 144; 205; 259; 318 hr*ug/mL
Phase 1 N=40 Sleep and Healthy Aging Research on Depression for Younger Women
Anhedonia · Depression
Primary: Non-social (Monetary) Reward Response (Reward Learning and Sensitivity) — .563; .307; .309; .366 response bias — p=.16
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
N/A N=243 Total Hip Replacement Performance & Assessment
Hip Osteoarthritis
Primary: Surgeon Participant Intra-operative Motion Analysis — 171,967; 172,258; 150,505 Movement counts
Phase 1 N=192 Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Nemolizumab — 8.00; 7.51 micrograms per milliliter (mcg/mL)